HIMSS Accelerate Health Podcast

Startup Showcase 2021: DTX Med

August 05, 2021 Accelerate Health
HIMSS Accelerate Health Podcast
Startup Showcase 2021: DTX Med
Show Notes Transcript

In this episode, Accelerate Health's Mary Sheridan speaks with Rami Elsabeh, the Chief Product Officer of DTX Med. DTX Med is a Patient Reported Outcomes (PRO) platform that is expanding to include additional messaging and communications functions. DTX allows clinicians to automate and digitize the capture of patient-generated information, both pre and post-visit, that is often collected via paper forms today. In use for research and clinical care, DTX allows users to customize questions, presentations, and logic to accommodate a variety of clinical scenarios and includes analytics tools to help triage and report collected information to streamline workflows.

Rami offers several use cases where current users have deployed DTX including diabetes care and a spinal surgery clinic. The conversation then takes a look ahead at the growth of PRO and other patent-generated health data likely to continue in the post-COVID care world. Platforms like DTX are positioned to help practices whose digitization has been driven by COVID streamline these new workflows as care settles into a new normal.

Mary Sheridan:

Hello changemakers thanks for joining us for another special episode of the Accelerate Health podcast this week. I'm Mary Sheridan, Senior Manager for Accelerate Health here at HIMSS. As part of our monthly showcase of highlighting outstanding startups in digital health, we're joined today by Rami Elsabeh, Director of Research at Hudson MSO. And the Chief Product Officer of DTX Med, which we're highlighting today. Hello, Rami, thank you so much for joining us.

Rami Elsabeh:

Hi, Mary. Thanks for having me.

Mary Sheridan:

So let's get started by you telling us a little bit about what DTX Med does and how it was founded.

Rami Elsabeh:

Sure, so DTX Med is an electronic patient reported outcome tool that automates follow up patient care through seamless integration of clinical outcomes and patient surveys. And so it uses SMS messaging to provide a simple and seamless patient experience so that providers can reliably collect and act on patient outcome data. And, you know, the idea behind developing it was the founder, Dr. Abrams, and myself, we started developing it three years ago, as you know, Director of Research at Hudson MSO, I help medical practices with their research needs. And you know, many of the medical practices that I work with, they were using paper forms as part of their clinical research process and to collect patient outcomes. And we just found that to be very inefficient over time, it was, you know, it was a time burden on staff and patients, it affected response rate and the amount of data that can be collected, since, you know, it was a time burden. And many times patients were in pain or had certain mobility issues that prevented them from answering the surveys in the office. And so you know, it was inefficient, it affected the amount of data that can be collected, and it led to, you know, increased patient and staff dissatisfaction. And so, you know, we tried phone calls, emails, and several other modalities, and they were equally inefficient. And so, you know, we came up with the idea of why don't we use SMS messaging to automate this process, you know, text messaging is the number one form of communication these days with 90% of texts being read within the first three minutes. So it's a very powerful form of communication. And, you know, it's it's a largely untapped information gathering method with spent tremendous potential in healthcare. So that's really where the idea of developing detex came from. And, you know, once we started developing it with, you know, the practices that we work with, with their needs in mind, we realized the software has value outside of, you know, the practices we work with, especially with, you know, the ongoing shift in the healthcare industry to value based care where a lot more emphasis is being placed on patient reported measures and cost reduction methods.

Mary Sheridan:

And so I was looking looking on your website, Rami, give me kind of an example of what you guys typically are using this for. And the applications that you see for maybe the futures if before I'm heading in for a procedure, or for a trial I saw where you can send a questionnaire and what's your temperature, what's your blood pressure, things like that. That's all at the ready within someone's fingertips on their phone with a text message. So they don't have to worry about talking to them ahead of time, or, like you said, burden about filling out a paper form in office.

Rami Elsabeh:

Right, right, exactly. And so as you said, it's not it's not, it doesn't have to just be used for, you know, procedures or surgical specialties, which is practice that we work with. Those are their focus. It's, you know, one of the things unique things about DTX and differentiating factors is its versatility and the ability to customize. So you can create questions that can be tailored towards any clinical scenario and targeted to any patient population, which really allows clinicians to engage with patients in real time throughout their care episode, and allows for multiple use cases, right? So, you know, in the case that you mentioned, and how it's, you know, commonly being used the software, it can you can create these surveys and link them to a specific procedure date. Right, and, you know, so you wouldn't be able to actually program the system to send automated surveys before and after the procedure date. But aside from the procedures, you know, it any other use cases, for example, you know, with chronic disease management, chronic diseases, which is a big issue now, you know, it affects nearly 120 million Americans and accounts for 75% of us healthcare spending. It can be used for those patients to streamline treatment management. So, you know, for example, if I'm a primary care physician treating diabetic patients, I would be able to send, you know, outcome surveys, weekly, monthly, you know, I would decide what the surveys would you know, the content of the surveys their logic and how often they would be sent. So, For any sort of chronic disease management, you know, this tool can be very useful.

Mary Sheridan:

Yeah, I think that's fantastic. And so I know you've talked about some of the differentiators with the platform, already a ton of applications that I can see being useful, especially the customizable portion of it. But what does that look like on the back end, you touched a little bit on physicicn... physicians being able to aggregate the data with the patient data. What does that look like in terms of the reporting? And how does that help providers?

Rami Elsabeh:

Right, so kind of on the back end, DTX has robust analytics, and you know, the types of reporting that you can run through it, is varied. And so what it really is allowed, it has multiple dashboards and graphs that allow you to kind of view and analyze that aggregate and patient level data in real time and export anything that you need, you know, into Microsoft Excel. So you have these dashboards where you can, you know, filter the data according to patient demographics, diagnoses, any other variables that you want. And then you can also, you know, filter the patient outcome data, by the physician surveys, we call them quality surveys. So that'll allow you to risk stratify those patients in real time, right, if you send the physician survey, you know, asking the physician questions on the patient's comorbidities and risk factors, you'd be able to see, you know, both the physician responses and the patient responses, and then be able to, you know, compare how diabetic patients that to non diabetic patients and be able to kind of instantly risk stratify your patients, which is something very unique about DTX, this idea of these quality surveys, or these surveys that can be sent to the physician. And later, you know, using that data to later Later merge it with the with the outcome data, I would say the very unique thing about DTS is it allows users to compare outcomes from similar disease processes, among other registered user groups, oh, wow, essentially allows you to benchmark your results against, you know, similar user groups in DTS, right. So if I'm, if I'm a spine surgery practice, you know, using dcx, to ask surveys for some of my surgeries, when I look at my data, I be able to instantly benchmark it to the aggregate data from all other spine practices using vt x in the same way. So it provides, you know, instant benchmarking as well, to give you an idea of, you know, how you're doing compared to others who are using the software, which is, you know, very valuable.

Mary Sheridan:

That's, that's amazing. And with the shifting, as we all know, this past year, year and a half now Jeez Its since COVID. We know obviously, there's a major shift to telehealth, what have you guys seen, I'm imagining you're seeing an increase in adoption of DTX on your platforms. But what benefits? Have you seen come out of this typical time? And what challenges are you guys still facing with adoption or maybe other parts of the platform?

Rami Elsabeh:

You know, to touch on COVID, you know, the value of using DTX, as a digital terror care tool, I think was more apparent than ever during COVID. Right? It expanded access to care by allowing physicians to touch base with and treat patients remotely, right. So since patient didn't have to come to the office, it really removed that barrier of care. And in the process of doing so, it, you know, reduced disease exposure for staff and patients, and that reduced patient demand on facilities. So I think it was during COVID, its value really showed, you know, moving forward, there's going to be a lot more emphasis on remote patient monitoring telehealth, you know, treating patients remotely. And so I think, you know, adoption, I expect adoption of DTX to increase and it has been increasing in the past year.

Mary Sheridan:

Yeah, I see it increasing as well, especially because it seems like you guys have been very thoughtful, and how you've created it thinking not just from the patient side, which is helpful, but also from the provider side as well. Not just the dashboard, the analytics of it, you know, saving them all those in between steps, making it more secure. I definitely see this being a very useful and almost mandatory platform for providers.

Rami Elsabeh:

You know, one of the things that I think will help you DTX is, you know, physicians can get reimbursed for using the software. They can, you know, build certain CMS virtual care and telehealth codes. So that's kind of a nice added benefit to you. Absolutely.

Mary Sheridan:

Yeah. Great. Yeah, there's an entire shift in the industry that's happening, like you said, a platform like yours is, is ahead of the curve, and people are starting to waking up to understand the necessity for it. So in that regard, as Chief Product officer, what are you most excited about? What's next for detex med? What are you excited about and where where are your plans to take it in the let's, let's say five to 10 Yours?

Rami Elsabeh:

Well, I would say, you know, we actually just recently developed an appointment confirmation functionality and the software, so allowing patients to confirm their appointments and answer outcome questions or other questions simultaneously, as a whole, I think it adds a whole new dimension to our tool. You know, it allows you to collect outcomes, but also serves another need. And then moving forward, you know, just continuing to refine the software based on feedback that we receive, you know, the TX was developed by medical professionals, so patient care really is at the center of how the software functions. And so you know, I'm excited to see how we can improve the software moving forward, based on the feedback we get, and, you know, continue to refine it, while still keeping patient care at the center and making that, you know, the most important thing, so far, it's, you know, we've we've implemented it at, it's been implemented at, you know, several practices, but the ones that, you know, kind of started this process, the ones that had this need that we initially developed the software for, you know, the one of them was a major neurosurgery, spine practice. And, you know, after implementing DTS x for about six months, they saw huge improvements in their, in their clinical research workflow, you know, patient response rate doubled. Oh, wow. You know, the mean time required to collect these outcomes actually was reduced by two thirds. So that's very exciting. So initial results are excellent. You know, I hope to continue to see those results at the other practices where GTX is being implemented. And then you know, as we continue to refine the software and improve it, kind of, you know, improve on those results and, and streamline the workflow as much as possible.

Mary Sheridan:

Absolutely. And that's it. Such exciting news and results from you guys from just the few use cases that you guys have listed here today, which I know is would just make it very enticing for any healthcare provider to want to jump on board. So we're very excited to amplify your message notes only great things ahead for you guys. And I want to take a time to thank you again, Romney for sharing your expertise and incredible company with us today. So to learn a little bit more about detects med, go ahead and visit their website at DT x med.com. And if you can't make it in person to hims 21 in Vegas this year in August, be sure to make your way over to the startup Park within innovation live to visit Rami and the entire GTX med team in person to see what's going on. Obviously a lot of exciting new things to come. And I can't wait to hear more from you guys over the next year or so.

Rami Elsabeh:

Sounds great. Mary, thanks. I look forward to seeing you there.

Mary Sheridan:

Thank you all for listening and keep on accelerating.